For sales

Highlights from the Week of 30th March 2026 – 6th April 2026 in the world of pharma and healthcare!

( FDA, Approval ) Highlights from the Week of 30th March 2026 - 6th April 2026 Eli Lilly receives FDA approval for FOUNDAYO, the first and only non-peptide, oral GLP-1 receptor agonist for chronic weight management Biogen's SPINRAZA 50 mg/5 mL and 28 mg/5 mL receives FDA approval for the treatment of spinal muscular atrophy FDA grants approval to Teva's PONLIMSI, a PROLIA biosimilar, for all indications of the reference product, followed by a review acceptance for its XOLAIR by the FDA and EMA ( FDA, Approval ) ( FDA, Approval ) ( FDA, Approval ) Pg 1/6 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.